The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1531
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The full article is available to subscribers Subscriber Login   

The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.

HCV GENOTYPES — HCV genotype 1 accounts for about 75% of HCV infections in the US, genotypes 2 and 3 account for about 20-25% of infections, genotype 4 for about 6%, and genotypes 5 and 6 for ≤1%. Genotype testing is recommended to determine the optimal treatment regimen.

TREATMENT OPTIONS FOR DAA-EXPERIENCED PATIENTS — Treatment of chronic HCV infection with DAAs results in sustained virologic response (SVR) rates of >90% in treatment-naive patients and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
Article code: 1531b
 Electronic, downloadable article - $25